Skip to main content

Generalized Myasthenia Gravis clinical trials at UC Irvine
1 in progress, 0 open to new patients

  • Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis

    Sorry, in progress, not accepting new patients

    The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with generalized Myasthenia Gravis (gMG). Subjects will be randomized in a 1:1:1 ratio to receive daily SC doses of 0.1 mg/kg RA101495, 0.3 mg/kg RA101495, or matching placebo for 12 weeks.

    Orange, California and other locations

Last updated: